NL-OMON20587招募中不适用
Stepwise Medical Treatment of Cushing’s Disease: a prospective, open label, multi-center trial with SOM230 mono- and combination therapy with dopamine agonists and ketoconazole for treatment of Cushing’s disease
Erasmus MCDpt. of Internal Medicine, Endocrine SectionRotterdamThe Netherlands0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 16
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Both naïve patients with Cushing’s disease and patients with residual hypercortisolism after recent transsphenoidal adenomectomy are eligible for enrolment.
- •2. Finally, patients with recurrent Cushing’s disease can also be included.
排除标准
- •1. Patients with poorly controlled diabetes mellitus indicated by a HbA1c % > 8.5 %.
- •2. Patients with a disturbed liver function indicated by serum bilirubin, ALAT, ASAT or alkaline phosphatase levels > 2.5 x ULN.
研究者
相似试验
进行中（未招募）
不适用
Stepwise Medical Treatment of Cushing’s Disease: a prospective open label multi-center trial with SOM230 mono- and combination therapy with dopamine agonists and ketoconazole - Stepwise Medical Treatment of Cushing's DiseaseThe medical condition to be investigated is Cushing's disease which is caused by an ACTH producing pituitary adenomaMedDRA version: 8.1Level: LLTClassification code 10011651Term: Cushing's diseaseEUCTR2006-004080-55-NLErasmus MC
招募中
2 期
Stepwise Medical Treatment of Cushing*s Disease: a prospective open label multi-center trial with SOM230 mono- and combination therapy with dopamine agonists and ketoconazoleNL-OMON30660Erasmus MC, Universitair Medisch Centrum Rotterdam16
招募中
不适用
Collecting Information About Treatment Results for Patients With Cushing's SyndromeCushing's DiseaseCushing DiseaseCushing SyndromeNCT03364803Memorial Sloan Kettering Cancer Center300
进行中（未招募）
1 期
Treating side effects of steroid medicatioAdverse effects of prescribed glucocorticoid therapyMedDRA version: 19.0Level: LLTClassification code 10068501Term: Cushing's syndrome, steroid-inducedSystem Organ Class: 100000004860EUCTR2016-003060-40-GBniversity of Oxford, Clinical Trials and Research Governance32
已完成
2 期
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's DiseaseCushing DiseaseNCT00171951Novartis Pharmaceuticals19